|
|
|
|
|
|
Sponsored by: |
Pfizer |
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00445315 |
Assess the safety, tolerability and pharmacokinetics of multiple oral doses of PF-00868554 in HCV positive patient volunteers
Condition | Intervention | Phase |
Hepatitis C |
Drug: PF-00868554 Drug: Placebo |
Phase I Phase II |
MedlinePlus related topics: | Hepatitis Hepatitis C |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Single Group Assignment, Safety Study |
Official Title: | A Phase 1, Randomized, Double Blind (3rd Party Open), Placebo-Controlled, Sequential Group, Multicentre Study To Evaluate The Multiple Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics, of PF-00868554 in Hepatitis C Virus (HCV) Positive Otherwise Healthy Patient Volunteers |
Enrollment: | 33 |
Study Start Date: | January 2007 |
Study Completion Date: | May 2008 |
Primary Completion Date: | May 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
2: Experimental |
Drug: PF-00868554
450 mg BID
|
3: Experimental |
Drug: PF-00868554
100 mg BID
|
1: Experimental |
Drug: PF-00868554
300 mg BID
|
4: Experimental |
Drug: PF-00868554
300 mg TID
|
5: Placebo Comparator |
Drug: Placebo
Placebo
|
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Belgium | |||||
Pfizer Investigational Site | |||||
Bruxelles, Belgium, 1070 | |||||
Germany | |||||
Pfizer Investigational Site | |||||
Berlin, Germany, 10117 | |||||
Pfizer Investigational Site | |||||
Berlin, Germany, 12351 | |||||
United Kingdom | |||||
Pfizer Investigational Site | |||||
Dundee, United Kingdom, DD1 9SY |
Pfizer |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
To obtain contact information for a study center near you, click here. 
  |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A8121002 |
First Received: | March 6, 2007 |
Last Updated: | July 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00445315 |
Health Authority: | United States: Food and Drug Administration |
|
|
|